- Home
- MRNA vs TOL Comparison
MRNA vs TOL Comparison
Compare MRNA & TOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- TOL
- Stock Information
- Founded
- MRNA 2010
- TOL 1967
- Country
- MRNA United States
- TOL United States
- Employees
- MRNA N/A
- TOL N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- TOL Homebuilding
- Sector
- MRNA Health Care
- TOL Consumer Discretionary
- Exchange
- MRNA Nasdaq
- TOL Nasdaq
- Market Cap
- MRNA 10.6B
- TOL 9.8B
- IPO Year
- MRNA 2018
- TOL N/A
- Fundamental
- Price
- MRNA $26.56
- TOL $104.23
- Analyst Decision
- MRNA Hold
- TOL Buy
- Analyst Count
- MRNA 19
- TOL 16
- Target Price
- MRNA $48.13
- TOL $139.13
- AVG Volume (30 Days)
- MRNA 14.2M
- TOL 1.8M
- Earning Date
- MRNA 05-01-2025
- TOL 05-20-2025
- Dividend Yield
- MRNA N/A
- TOL 0.96%
- EPS Growth
- MRNA N/A
- TOL N/A
- EPS
- MRNA N/A
- TOL 13.50
- Revenue
- MRNA $3,177,000,000.00
- TOL $10,659,614,000.00
- Revenue This Year
- MRNA N/A
- TOL N/A
- Revenue Next Year
- MRNA $8.98
- TOL $3.41
- P/E Ratio
- MRNA N/A
- TOL $7.72
- Revenue Growth
- MRNA N/A
- TOL 1.59
- 52 Week Low
- MRNA $23.15
- TOL $86.67
- 52 Week High
- MRNA $158.82
- TOL $169.52
- Technical
- Relative Strength Index (RSI)
- MRNA 50.60
- TOL 50.41
- Support Level
- MRNA $25.22
- TOL $101.92
- Resistance Level
- MRNA $27.15
- TOL $107.95
- Average True Range (ATR)
- MRNA 1.61
- TOL 2.79
- MACD
- MRNA 0.26
- TOL -0.18
- Stochastic Oscillator
- MRNA 47.66
- TOL 26.40
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About TOL Toll Brothers Inc.
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US It has its headquarters in Horsham, Pennsylvania.